IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.596
-0.078 (-4.66%)
Mar 5, 2026, 9:24 AM CET

IRLAB Therapeutics AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
57.4694.635.6861.14207.78
57.4694.635.6861.14207.78
Revenue Growth (YoY)
-39.28%1566.57%-90.71%-70.58%69160.67%
Cost of Revenue
99.38136.29128.41125.9181.74
Gross Profit
-41.91-41.66-122.73-64.77126.05
Selling, General & Admin
46.1246.1853.0842.4831.02
Other Operating Expenses
1.05-19.46-0.04-0.0338.97
Operating Expenses
51.4831.3157.3647.2373.47
Operating Income
-93.4-72.97-180.09-11252.58
Interest Expense
-17.99-10.48-0.2-0.3-0.37
Interest & Investment Income
1.382.463.13-0
Currency Exchange Gain (Loss)
--2.14-0.68-1.11-0.43
Other Non Operating Income (Expenses)
-0-0--
EBT Excluding Unusual Items
-110.01-83.13-177.84-113.4151.78
Pretax Income
-110.01-83.13-177.84-113.4151.78
Earnings From Continuing Operations
-110.01-83.13-177.84-113.4151.78
Net Income
-110.01-83.13-177.84-113.4151.78
Net Income to Common
-110.01-83.13-177.84-113.4151.78
Shares Outstanding (Basic)
6752525252
Shares Outstanding (Diluted)
6752525252
Shares Change (YoY)
29.17%-0.07%0.16%8.54%
EPS (Basic)
-1.64-1.60-3.43-2.191.00
EPS (Diluted)
-1.64-1.60-3.43-2.191.00
Free Cash Flow
-55.22-65.79-165.14-145.49127.93
Free Cash Flow Per Share
-0.82-1.27-3.18-2.812.47
Gross Margin
-72.94%-44.03%--105.94%60.66%
Operating Margin
-162.54%-77.11%-3171.72%-183.20%25.30%
Profit Margin
-191.45%-87.85%-3132.07%-185.50%24.92%
Free Cash Flow Margin
-96.10%-69.52%-2908.47%-237.97%61.57%
EBITDA
-89.08-72.08-179.17-111.2753.07
EBITDA Margin
-155.02%-76.17%--182.00%25.54%
D&A For EBITDA
4.320.890.920.740.49
EBIT
-93.4-72.97-180.09-11252.58
EBIT Margin
-162.54%-77.11%--183.20%25.30%
Revenue as Reported
62.8114.085.7261.28207.91
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.